Daily Stock Analysis, AVEO, Aveo Pharmaceuticals Inc, priceseries

Aveo Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
3.07
Close
3.11
High
3.15
Low
2.99
Previous Close
3.06
Daily Price Gain
0.05
YTD High
4.24
YTD High Date
Aug 28, 2017
YTD Low
0.50
YTD Low Date
Mar 28, 2017
YTD Price Change
2.51
YTD Gain
415.50%
52 Week High
4.24
52 Week High Date
Aug 28, 2017
52 Week Low
0.50
52 Week Low Date
Mar 28, 2017
52 Week Price Change
2.48
52 Week Gain
394.75%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 26. 2015
0.95
Mar 16. 2015
1.30
12 Trading Days
37.19%
Link
LONG
May 19. 2015
1.34
Jun 9. 2015
2.24
14 Trading Days
67.31%
Link
LONG
May 25. 2016
0.92
Jun 10. 2016
1.03
11 Trading Days
12.29%
Link
LONG
Jun 22. 2017
0.73
Jul 17. 2017
2.50
16 Trading Days
243.45%
Link
LONG
Aug 10. 2017
2.79
Aug 29. 2017
3.17
13 Trading Days
13.70%
Link
Company Information
Stock Symbol
AVEO
Exchange
NasdaqGS
Company URL
http://http://www.aveooncology.com
Company Phone
617- 531-2130
CEO
Michael P. Bailey
Headquarters
Massachusetts
Business Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001325879
About

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. The company's pipeline of product candidates include Tivozanib, an tyrosine kinase inhibitor for various vascu...

Description

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. The company's pipeline of product candidates include Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors for renal cell carcinoma and other cancers; Ficlatuzumab, an anti-hepatocyte growth factor inhibitory antibody, which has completed Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380 Program, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia, which is a multi-factorial syndrome of involuntary weight loss associated with various cancers and diseases outside of cancer, including chronic kidney disease, congestive heart failure, and chronic obstructive pulmonary disease. It has strategic partnerships with Ophthotech Corporation; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec Inc.; and Kyowa Hakko Kirin. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.